Home » GSK Melanoma Combination Drug Takes on Roche’s Zelboraf in Phase III Trial
GSK Melanoma Combination Drug Takes on Roche’s Zelboraf in Phase III Trial
GlaxoSmithKline stirred up cancer circles this month when release of some clinical data of its melanoma treatment suggested that the experimental combination drug could work better than Roche’s Zelboraf.
MedCity News
MedCity News
Upcoming Events
-
07May
-
14May
-
30May